Patents by Inventor Mark Currie

Mark Currie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050020811
    Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: March 9, 2004
    Publication date: January 27, 2005
    Inventors: Mark Currie, Shalina Mahajan-Miklos
  • Publication number: 20050009798
    Abstract: Compositions containing ?2 adrenergic agonists in combination with carbonates and carbamates of the formula and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.
    Type: Application
    Filed: August 1, 2003
    Publication date: January 13, 2005
    Applicant: SEPRACOR INC.
    Inventors: Mark Currie, Steve Jones, Paul Grover, Chris Senanayake, Q. Fang
  • Publication number: 20050004104
    Abstract: The invention features certain compounds useful in the treatment of memory disorders, i.e., they reduce or delay memory loss or they enhance memory retention. Because certain of the compounds do not substantially inhibit either COX-1 or COX-2 at therapeutically relevant doses, these compounds are far less likely to cause gastrointestinal ulceration than is indomethacin, which is known to inhibit both COX-1 and COX-2. Certain of the compounds inhibit the activity of DAO at therapeutically relevant doses. Among the memory disorders that can be treated are AD, mild cognitive impairment (MCI; a common precursor to AD), and memory loss or cognitive impairment associated with vascular dementias, amnesia, dementia, AIDS dementia, Huntington's Disease, hydrocephalus, depression, Pick's Disease, Creutzfeldt-Jakob Syndrome, electroconvulsive therapy, or Parkinson's Disease.
    Type: Application
    Filed: June 1, 2004
    Publication date: January 6, 2005
    Inventors: Brian Cali, Yueh-Tyng Chien, Mark Currie, John Talley, Craig Zimmerman
  • Patent number: 6780891
    Abstract: Compounds of formula I are effective in treating disorders modulated by opiate receptor activity and/or monoamine activity. In formula I, R1 is selected from alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl; R2 is selected from hydrogen, hydroxy, cyano, haloalkyl, glycosyl, SO2R5, and OR5; R3 and R4 are independently selected from hydrogen and lower alkyl, or R3 and R4 taken together with nitrogen form a five- or six-membered heterocyclic or substituted heterocyclic ring; and R5 is selected from alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: August 24, 2004
    Assignee: Sepracor Inc.
    Inventors: Chris Hugh Senanayake, Thomas P. Jerussi, Paul T. Grover, Qun Kevin Fang, Mark Currie
  • Publication number: 20030171440
    Abstract: Compounds of formula I are effective in treating disorders modulated by opiate receptor activity and/or monoamine activity.
    Type: Application
    Filed: December 2, 2002
    Publication date: September 11, 2003
    Applicant: SEPRACOR INC.
    Inventors: Chris Hugh Senanayake, Thomas P. Jerussi, Paul T. Grover, Qun Kevin Fang, Mark Currie
  • Patent number: 6592020
    Abstract: The invention relates to a lead-free solder paste comprising a solder paste flux and solder alloy particles that are substantially lead-free wherein the solder paste flux comprises resin dissolved in a solvent and also includes undissolved resin particles less than 25 &mgr;m in size homogenously dispersed therein to provide improved solder alloy powder coalescence and substrate surface wetting while maintaining appropriate solder paste rheology for use in printed circuit board assembly processes.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: July 15, 2003
    Assignee: Henkel Loctite Adhesives Limited
    Inventors: Mark Currie, Angelo Elyassi, Grahame Freeman, Malcolm Warwick, Ian Wilding
  • Publication number: 20020022032
    Abstract: Immuno-adjuvant photodynamic therapy to treat and prevent metastatic cancer is effected using photosensitizers in combination with immuno-adjuvants to destroy metastatic tumor cells.
    Type: Application
    Filed: January 9, 2001
    Publication date: February 21, 2002
    Inventors: Patrick Mark Curry, Anna M. Richter, Julia G. Levy, David W.C. Hunt